Related Experiment Video
Updated: Jun 13, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Effect of butylscopolamine on image quality in MRI of the prostate
1Department of Radiology, Charité - Universitätsmedizin Berlin, Germany. moritz.wagner@charite.de
Aim:
To evaluate the impact of butylscopolamine on the quality of magnetic resonance imaging (MRI) images of the prostate.
Material And Methods:
Eighty-two MRI examinations of the prostate were retrospectively analysed. MRI was performed with a combined endorectal/body phased-array coil including proton density-weighted (PD) sequence, T1-weighted turbo spin-echo (TSE)-sequence, and T2-weighted TSE-sequences. Forty milligrams of butylscopolamine was administered intramuscularly in 31 patients (im-group) and intravenously in 30 patients (iv-group). Twenty-one patients did not receive premedication with butylscopolamine (ø-group). Overall image quality, delineation of the bowel wall, and visualization of the prostate, neurovascular bundle, and pelvic lymph nodes were evaluated qualitatively using a five-point scale (from 1=excellent to 5=non-diagnostic/structure not discernible). Motion artefacts within the endorectal coil were quantified by baseline adjusted signal intensities inside the endorectal coil area.
Results:
Delineation of the bowel wall using the PD-sequence was significantly improved after both intramuscular and intravenous butylscopolamine administration (ø-group: 3.6+/-0.7; im-group: 2.9+/-0.7; iv-group: 2.9+/-0.7; p=0.001). However, there were no significant differences in motion artefacts measured within the endorectal coil (ø-group: 1.18+/-0.14; im-group: 1.15+/-0.11; iv-group: 1.12+/-0.06; p=0.39). There were also no significant differences in qualitative assessment of visualization of the prostate, neurovascular bundle, pelvic lymph nodes, and of overall image quality between the study groups.
Conclusion:
: In conclusion, butylscopolamine had only a small effect on image quality and is not mandatory for MRI of the prostate.
Insights
Butylscopolamine improved bowel wall delineation in prostate MRI but did not significantly reduce motion artifacts. This drug is not essential for high-quality prostate MRI examinations.
Area of Science:
- Radiology
- Medical Imaging
- Gastrointestinal Imaging
Background:
- Prostate MRI quality is crucial for accurate diagnosis.
- Motion artifacts and bowel wall visualization can impact image interpretation.
- Butylscopolamine is sometimes used to reduce gastrointestinal motility.
Purpose of the Study:
- To assess the effect of butylscopolamine on prostate MRI quality.
- To evaluate its impact on image artifacts and visualization of key structures.
Main Methods:
- Retrospective analysis of 82 prostate MRI scans.
- Butylscopolamine administered intramuscularly or intravenously in patient groups.
- Image quality assessed qualitatively and motion artifacts quantified.
Main Results:
- Butylscopolamine significantly improved bowel wall delineation on PD-weighted sequences.
- No significant reduction in motion artifacts within the endorectal coil was observed.
- Overall image quality and visualization of prostate, neurovascular bundle, and lymph nodes were not significantly different between groups.
Conclusions:
- Butylscopolamine offers limited benefit for overall prostate MRI quality.
- It may improve bowel wall visualization but is not a mandatory adjunct.
- Further research could explore optimal protocols for motion reduction in prostate MRI.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies for Cardiovascular System IV: CMRI
